Evidence mapPaperPMID 38596283Full record

ArticleClinicoEconomics and outcomes research : CEOR2024

Cost-Savings Associated with Multi-Disciplinary Team Approach for Reducing Macrovascular and Microvascular Complications in Patients with Type 2 Diabetes: A Predictive Model.

Abdulmajeed Alshowair, Saleh Altamimi, Faisal A Alruhaimi, Saad Alshahrani, Fatima Alsuwailem, Mona Alkhaldi, Haiam Abdalla, Fahad Hamad Alkhuraiji, Montaser Saad Alaqeel, Salman Sulaiman Almureef and 2 more

Open access · goldAbstract read
In one paragraph

Article in ClinicoEconomics and outcomes research : CEOR, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
6.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Abdulmajeed AlshowairCommunity Health Excellence, Riyadh First Health Cluster Ministry of Health, Riyadh, Saudi Arabia.ORCID 0000-0003-2871-274X
Saleh AltamimiCommunity Health Excellence, Riyadh First Health Cluster Ministry of Health, Riyadh, Saudi Arabia.
Faisal A AlruhaimiCommunity Health Excellence, Riyadh First Health Cluster Ministry of Health, Riyadh, Saudi Arabia.
Saad AlshahraniAcademic and Training Affairs, Riyadh First Health Cluster Ministry of Health, Riyadh, Saudi Arabia.ORCID 0000-0002-4454-921X
Fatima AlsuwailemPopulation Health Management and Research, Riyadh First Health Cluster Ministry of Health, Riyadh, Saudi Arabia.
Mona AlkhaldiHealth Administration Office, Riyadh First Health Cluster Ministry of Health, Riyadh, Saudi Arabia.
Haiam AbdallaModel of Care, Riyadh First Health Cluster Ministry of Health, Riyadh, Saudi Arabia.
Fahad Hamad AlkhuraijiFinancial Affairs, Riyadh First Health Cluster Ministry of Health, Riyadh, Saudi Arabia.
Montaser Saad AlaqeelFinancial Affairs, Riyadh First Health Cluster Ministry of Health, Riyadh, Saudi Arabia.
Salman Sulaiman AlmureefCost Department, Riyadh First Health Cluster Ministry of Health, Riyadh, Saudi Arabia.
Salman AlhawasyReporting Department, Riyadh First Health Cluster Ministry of Health, Riyadh, Saudi Arabia.
Amro Abdel-AzeemPopulation Health Management and Research, Riyadh First Health Cluster Ministry of Health, Riyadh, Saudi Arabia.ORCID 0000-0001-8607-1536
Ministry of Health · SAZagazig University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: This study aims to predict the expected cost savings associated with implementing a multidisciplinary team (MDT) approach to reduce macrovascular and microvascular complications among patients with type 2 diabetes mellitus (T2DM). Methods: This economic evaluation study was conducted in Riyadh First Health Cluster, Saudi Arabia as a predictive model conceptualized by the authors based on models used in previous studies, particularly the CORE Diabetes Model. Our model was designed based on 1) the level of glycemic control among 24,755 T2DM patients served by MDTs; 2) the expected incidence of diabetes-related complications without intervention; 3) the predicted risk reduction of developing diabetes-related complications with MDTs. Costs of complications and cost savings were then calculated and expressed as mean incremental annual cost savings adjusted for a 1% reduction in HbA1c, and a 10 mmHg reduction in systolic blood pressure (SBP). Results: Along with the expected reduction in all diabetes-related complications, the average incremental cost savings per diabetic patient is predicted to be ($38,878) with approximately ($11,108) in the year of complication onset and ($27,770) over the subsequent post-index 10-years. On adjustment of cost savings, the average incremental cost savings are predicted to be ($22,869) for each 1% reduction in HbA1c per diabetic patient and ($27,770) for every 10 mmHg reduction in SBP per diabetic patient. Conclusion: MDT as a model of care is effective in glycemic control among T2DM patients with a predicted significant reduction of all diabetes-related complications and in turn, a predicted significant cost savings.

Indexed as

complicationscost-savingsmulti-disciplinary teampredictive modeltype 2 diabetes

Identifiers

PMID38596283
PMCPMC11001564
OpenAlexW4393948226

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.